Free Trial

Xenon Pharmaceuticals (XENE) SEC Filings & 10K Form

$41.90
-1.02 (-2.38%)
(As of 07/15/2024 ET)

Recent Xenon Pharmaceuticals SEC Filings

DateFilerForm TypeView
07/12/2024
8:44 PM
PIMSTONE SIMON N. (Reporting)
Xenon Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/12/2024
4:32 PM
ROBIN SHERRINGTON (Reporting)
Xenon Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/05/2024
4:42 PM
GANNON STEVEN (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2024
4:42 PM
GAROFALO ELIZABETH A. (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2024
4:42 PM
Gover Justin D. (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2024
4:42 PM
Machado Patrick (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2024
4:43 PM
PATOU GARY (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2024
4:41 PM
Svoronos Dawn (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2024
4:41 PM
Cannon Gillian (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2024
4:30 PM
PIMSTONE SIMON N. (Reporting)
Xenon Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/05/2024
3:22 PM
Xenon Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
06/05/2024
3:12 PM
Xenon Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/09/2024
3:09 PM
Xenon Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/26/2024
3:26 PM
Xenon Pharmaceuticals (Filer)
Form DEF 14A
04/19/2024
3:21 PM
Xenon Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/12/2024
5:41 PM
AULIN SHERRY (Reporting)
Xenon Pharmaceuticals (Issuer)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2024
5:42 PM
Von Seggern Christopher (Reporting)
Xenon Pharmaceuticals (Issuer)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2024
5:33 PM
MORTIMER IAN (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2024
5:34 PM
DiFabio Andrea (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2024
5:35 PM
ROBIN SHERRINGTON (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2024
5:37 PM
EMPFIELD JAMES R. (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2024
5:38 PM
KENNEY CHRISTOPHER JOHN (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/11/2024
7:09 PM
GAROFALO ELIZABETH A. (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/08/2024
5:47 PM
GAROFALO ELIZABETH A. (Reporting)
Xenon Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/08/2024
4:27 PM
Xenon Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/08/2024
4:28 PM
GANNON STEVEN (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/08/2024
4:31 PM
ROBIN SHERRINGTON (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/07/2024
6:03 PM
GANNON STEVEN (Reporting)
Xenon Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/07/2024
6:04 PM
ROBIN SHERRINGTON (Reporting)
Xenon Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/29/2024
3:36 PM
Xenon Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/29/2024
3:10 PM
Xenon Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/14/2024
8:12 AM
Avoro Capital Advisors LLC (Filed by)
Xenon Pharmaceuticals (Subject)
Form SC 13G/A
02/14/2024
6:43 AM
DRIEHAUS CAPITAL MANAGEMENT LLC (Filed by)
Xenon Pharmaceuticals (Subject)
Form SC 13G/A
02/09/2024
9:05 AM
FMR LLC (Filed by)
Xenon Pharmaceuticals (Subject)
Form SC 13G/A
01/02/2024
3:41 PM
ROBIN SHERRINGTON (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/20/2023
4:04 PM
AZAB MOHAMMAD (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2023
8:50 PM
PATOU GARY (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4/A
12/15/2023
4:38 PM
PATOU GARY (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/13/2023
7:02 PM
PATOU GARY (Reporting)
Xenon Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/29/2023
4:05 PM
Xenon Pharmaceuticals (Filer)
Form 424B5
11/27/2023
6:03 AM
Xenon Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
This $0.30 AI Stock Could Revolutionize Public Safety (Ad)

This AI security pioneer saw a 128% revenue surge in 2023, hitting $12.8 million. Yet it has a market cap of just $35 million. Here's the kicker: The security robots market is projected to reach $120 billion by 2030.

Uncover the full story behind this $0.30 AI security game-changer now.
08/24/2023
3:27 PM
Svoronos Dawn (Reporting)
Xenon Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/24/2023
3:33 PM
Svoronos Dawn (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/10/2023
5:40 PM
Cannon Gillian (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
08/10/2023
5:56 PM
Cannon Gillian (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/10/2023
6:00 PM
Gover Justin D. (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
08/10/2023
6:05 PM
Gover Justin D. (Reporting)
Xenon Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:XENE) was last updated on 7/16/2024 by MarketBeat.com Staff

From Our Partners